HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
HCID 14743Erstellt: 4. November 2026
17β-Hydroxyandrost-4-en-3-on-3-phenylpropionat
Test phenylpropionate · Nphen · Test PP · Test npp · retandrol · Test phen · Stosterone · Test pheny
https://huagongshe.com/de/chemical/14743
Identifikatoren & physikalische Daten
| CAS No. | 1255-49-8 |
|---|
| Summenformel | C28H36O3 |
|---|
| Durchschnittliche Molmasse | 420,6 g/mol |
|---|
| Monoisotopische Masse | 420,26644501 g/mol |
|---|
| SMILES | C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2OC(=O)CCc1ccccc1 |
|---|
| InChIKey | HHSXYDOROIURIP-FEZCWRLCSA-N |
|---|
| PubChem CID | 14743 |
|---|
| ChEMBL | CHEMBL2356993 |
|---|
| ChEBI | CHEBI:35002 |
|---|
| EC No. | 215-014-4 |
|---|
| DTXSID | DTXSID5048712 |
|---|
| Lokaler Name | 17β-Hydroxyandrost-4-en-3-on-3-phenylpropionat |
|---|
Chemische & physikalische Eigenschaften
| XLogP | 5,8 |
|---|
| Polarare Oberfläche (TPSA) | 43,4 |
|---|
| H-Brücken-Donoren | 0 |
|---|
| H-Brücken-Akzeptoren | 3 |
|---|
| Frei drehbare Bindungen | 5 |
|---|
| Schwere Atome | 31 |
|---|
| Formalladung | 0 |
|---|
| Komplexität | 747 |
|---|
| Arzneimittel | Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds |
|---|
| Human Drugs | Pharmaceuticals |
|---|
| Endocrine Disruptors | Potential endocrine disrupting compound |
|---|
| Schmelzpunkt | 116.5 °C |
|---|
| Siedepunkt | 497.74°C (rough estimate) |
|---|
| Dichte | 1.0043 (rough estimate) |
|---|
| Brechungsindex | 1.5460 (estimate) |
|---|
| Löslichkeit | DMF: 25 mg/mLDMSO: 5 mg/mLEthanol: 15 mg/mLEthanol:PBS (pH 7.2)(1:2): 0.3 mg/mL2.25mg/L(25 ºC) |
|---|
| InChIKey | HHSXYDOROIURIP-FEZCWRLCSA-N |
|---|
| SMILES | [C@@]12(CC[C@]3(C)[C@H](CC[C@@]3([H])[C@@]1(CCC1=CC(=O)CC[C@]21C)[H])OC(=O)CCC1C=CC=CC=1)[H] |&1:0,3,5,8,10,19,r| |
|---|
| CAS Datenbank | 1255-49-8(CAS DataBase Reference) |
|---|
Sicherheit & Vorschriften
| GHS-Einstufung | DangerH302 (96.6%): Harmful if swallowed [Warning Acute toxicity, oral]P203, P260, P261, P264, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P317, P318, P319, P321, P330, P362+P364, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 58 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|
| Regulatorische Informationen | Testosterone phenyl propionate: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right. |
|---|
| Weitere Sicherheitsinformationen | IMAP assessments - Androst-4-en-3-one, 17-(1-oxo-3-phenylpropoxy)-, (17.beta.)-: Human health tier I assessment |
|---|
| Hazard Classes and Categories | Acute Tox. 4 (96.6%) |
|---|
| Wassergefährdungsklasse (WGK) | 3 |
|---|
| RTECS-Nr. | XA3105000 |
|---|
| R-Sätze (R) | 20/21/22-40 |
|---|
| Gefahrensymbole | Xn |
|---|
| Sicherheitshinweise (S) | 22-36 |
|---|
Anwendungen & Verwendung
Beschreibung
Testosterone phenylpropionate (BAN; TPP) (brand name Testolent), or testosterone phenpropionate, also known as testosterone hydrocinnamate, is a synthetic anabolic-androgenic steroid (AAS) and an androgen ester – specifically, the C17β phenylpropionate ester of testosterone – which was formerly marketed in Romania. It was first synthesized in 1951 and was first described in the literature by 1953. The medication was an ingredient of several isolated AAS commercial products, but was never widely used. Testosterone phenylpropionate was also notably a component of Sustanon and Omnadren, as well as of Estandron Prolongatum, Lynandron Prolongatum, and Mixogen. TPP was previously available in Great Britain.
